title: [Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma].
abstract: A 48-year-old man was referred to Sakai Municipal Hospital with nasal discharge and right facial swelling. The pathological findings of a nasal cavity tumor revealed stage IIB NK/T-cell lymphoma. He was admitted to our hospital and received CHOP therapy, resulting in progressive disease. Irradiation therapy combined with DeVIC chemotherapy also could not shrink his lymphoma. Then, two courses of L-asparaginase(L-Asp) were administered, resulting in partial improvement of the nasal and pharynx lesions, resolution of the fever and improvement of his performance status. On the day before a third course of L-Asp, he again developed a lowgrade fever. Although L-Asp was administered for several days, marked elevation of serum LDH, AST, ALT level, and thrombocytopenia persisted, and he died. Post-mortem examinations revealed hemophagocytosis in the bone marrow and liver, and infiltration of lymphoma cells into multiple organs including left lower lung, liver, spleen and kidneys. Although L-Asp was effective against nasal NK/T-cell lymphoma resistant to combination chemotherapy and irradiation therapy, the effectiveness of the single agent with L-Asp was only transient. L-Asp based regimen should be used as first-line therapy if asparagine synthetase protein expression is low using an immunohistochemical method.
authors.affiliation: Clinical Hematology and Clinical Diagnostics, Osaka City University, Graduate School of Medicine.
authors.forename: Erina
authors.initials: E
authors.lastname: Sakamoto
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yamane
authors.forename: Takahiko
authors.initials: T
authors.lastname: Nakane
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Takeoka
authors.forename: Asao
authors.initials: A
authors.lastname: Hirose
authors.forename: Kiyoyuki
authors.initials: K
authors.lastname: Hagihara
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Nakamae
authors.forename: Kensuke
authors.initials: K
authors.lastname: Ohta
authors.forename: Michihiko
authors.initials: M
authors.lastname: Hirayama
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Ikura
authors.forename: Masahiko
authors.initials: M
authors.lastname: Ohsawa
authors.forename: Toru
authors.initials: T
authors.lastname: Sawada
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kitoh
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hino
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D017809:Fatal Outcome; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology; D008113:Liver Neoplasms / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009669:Nose Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001215:Asparaginase